Last reviewed 2026-05-14 · How we verify

GSK Biologicals HIV Vaccine 732462

GlaxoSmithKline · Phase 2 active Biologic

GSK Biologicals HIV Vaccine 732462 is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Prevention of HIV infection.

This vaccine works by stimulating the body's immune system to produce a specific response against the HIV virus.

This vaccine works by stimulating the body's immune system to produce a specific response against the HIV virus. Used for Prevention of HIV infection.

At a glance

Generic name	GSK Biologicals HIV Vaccine 732462
Sponsor	GlaxoSmithKline
Modality	Biologic
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

The vaccine contains a weakened or inactivated form of the HIV virus, which triggers an immune response without causing the disease. This immune response helps the body to recognize and fight off the virus if it enters the body in the future.

Approved indications

Prevention of HIV infection

Common side effects

Injection site reactions
Fatigue
Headache

Key clinical trials

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK Biologicals HIV Vaccine 732462 CI brief — competitive landscape report
GSK Biologicals HIV Vaccine 732462 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about GSK Biologicals HIV Vaccine 732462

What is GSK Biologicals HIV Vaccine 732462?

GSK Biologicals HIV Vaccine 732462 is a Biologic drug developed by GlaxoSmithKline, indicated for Prevention of HIV infection.

How does GSK Biologicals HIV Vaccine 732462 work?

This vaccine works by stimulating the body's immune system to produce a specific response against the HIV virus.

What is GSK Biologicals HIV Vaccine 732462 used for?

GSK Biologicals HIV Vaccine 732462 is indicated for Prevention of HIV infection.

Who makes GSK Biologicals HIV Vaccine 732462?

GSK Biologicals HIV Vaccine 732462 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is GSK Biologicals HIV Vaccine 732462 in?

GSK Biologicals HIV Vaccine 732462 is in Phase 2.

What are the side effects of GSK Biologicals HIV Vaccine 732462?

Common side effects of GSK Biologicals HIV Vaccine 732462 include Injection site reactions, Fatigue, Headache.

Manufacturer: GlaxoSmithKline — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Prevention of HIV infection
Compare: GSK Biologicals HIV Vaccine 732462 vs similar drugs
Pricing: GSK Biologicals HIV Vaccine 732462 cost, discount & access